Abstract: A method for producing a polyphenol composition including a step of subjecting (A) a hardly water-soluble polyphenol and (B) one or more selected from cathechins, chlorogenic acids and methylated compounds of hardly water-soluble polyphenols to a heat treatment at from 100 to 180° C. in the presence of an aqueous medium.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: Disclosed is a method for preparing polysaccharides of green tea, and more particularly to a method for preparing polysaccharides of green tea comprising the steps of: a) removing chlorophyll and a low molecular weight polyphenol from green tea powder using a solvent; b) hot-water extracting a water-soluble active ingredient from the green tea residue of step a); and c) separating the polysaccharides of green tea from the hot-water extract of step b) by ultrafiltration and ethanol precipitation. Also, the present invention relates to a cosmetic composition for skin whitening, moisturization and anti-wrinkle effects comprising the polysaccharides of green tea as an effective ingredient.

Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

Abstract: The method for producing a mixture of neutral oligosaccharides extracted from flaxseed includes oligosaccharides having high molar masses generated by fractionation by ultrafiltration at a cut-off of between 15,000 and 50,000 Da and between 5,000 and 15,000 Da. The mixture of oligosaccharides produced as a result of the implementation of the method, and to the applications of the mixture can be used for skin repair and skin aging control.

Abstract: Provided is a method for easily producing a polyphenol composition in a solid state having an excellent solubility in water. The method for producing the polyphenol composition comprises the following steps (1) and (2): (1) heating a mixture of a hardly water-soluble polyphenol (A) and a water-soluble polyphenol (B) to a temperature equal to or higher than the lowest melting point or glass transition temperature of the hardly water-soluble polyphenol (A) or the water-soluble polyphenol (B), thereby obtaining a heat-treated solution, and (2) cooling and solidifying the thus-obtained heat-treated solution.

Abstract: It is the object of the present invention a composition containing an N-acyl-ethanolamine in a solubilized form, particularly a solution for ophthalmic, intra-articular or intravesical use. Particularly, the present invention relates to a water-soluble composition comprising one or more N-acylethanolamines (NAE) in the form of an inclusion complex in methyl-beta-cyclodextrin (M?CD).

Abstract: A crystalline modification V of emamectin benzoate, exhibiting at least 3 of the following reflexes in an X-ray powder diffractogram recorded using Cu—K? radiation at 25° C.: 2?=4.34±0.2??(1) 2?=10.58±0.2??(2) 2?=12.32±0.2??(3) 2?=15.19±0.2??(4) 2?=18.57±0.2??(5) 2?=20.41±0.2??(6) A process for the preparation of emamectin benzoate in the aforementioned form comprises i) preparing a solution of a solid form of emamectin benzoate in a solvent comprising ethyl acetate and n-hexane; ii) effecting crystallization of emamectin benzoate from the solution; and iii) isolating the emamectin benzoate formed. The crystalline modification V can be formulated to any suitable pesticidal formulations.

Abstract: The invention provides a propionate inulin ester for the reduction of appetite, food intake and/or calorie intake and/or to improve insulin sensitivity in a subject, and for the treatment or prevention of obesity or diabetes. The invention also provides compositions comprising a propionate inulin ester, methods using propionate inulin esters, functional food containing propionate inulin ester and methods of making propionate inulin esters.

Abstract: The present invention provides a method for preventing or treating hair loss or promoting hair growth, comprising secoiridoid glucoside derivatives or hydrolysate thereof as active ingredients. The present invention not only includes natural compounds as an active ingredient without side effects of the long-term treatment in a chronic disease hair loss, but also shows excellent effects for promoting hair growth with stable efficacy. Therefore, the present invention may be used as an effective pharmaceutical, cosmetic or functional food composition for preventing or treating hair loss or promoting hair growth.

Abstract: Ionically cross-linked compositions containing carboxypolysaccharides, polyalkylene oxides, polyhydroxyl organic anions, optionally divalent cations, and aqueous media are provided. Methods for manufacturing ionically cross-linked compositions of carboxypolysaccharides, polyalkylene oxides, polyhydroxyl organic anions, optionally divalent cations, and aqueous media are also provided. Such compositions can be used by placing then in proximity to a tissue in need of lubrication or for prevention of adhesions and adhesion reformation.

Abstract: This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid. In one embodiment, the glucocorticoid is dexamethasone. In another embodiment, the sustained-release system comprises a polymer such as e.g. polylactic-coglycolic acid.

Abstract: A method for manufacturing a modified hydroxyethyl starch carrying a heptonic acid residue on at least one of its termini. Within this method, the following steps are carried out: a) dissolving hydroxyethyl starch in water, b) adjusting the pH value to a value of 8.0 to 10.0, c) adding a cyanide compound to the hydroxyethyl starch solution, heating the solution to a temperature of 80 to 99° C. and keeping it at this temperature for a first time period, and d) adjusting the pH value to a value of 2.0 to 4.0, bringing the solution to a temperature of 50 to 90° C. and keeping it at this temperature for a second time period.

Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 30 to 44° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.

Abstract: An injectable hydrogel, includes, in weight, in a physiologically acceptable carrier fluid: 0.01 to 5% of glycerol and 0.1 to 5% of cross-linked hyaluronic acid, or one of the salts thereof; characterized in that the hyaluronic acid or one of the salts thereof is cross-linked by the formation of covalent bonds using bifunctional or polyfunctional molecules, the injectable hydrogel being sterilized in moist heat and having viscoelastic properties such that Tan ? at a frequency of 1 Hz is less than or equal to 1.10. A method for producing the hydrogel, to a kit containing the hydrogel, as well as to the use thereof in dermatology are also described.

Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersonmia; endozepine related recurrent stupor; and amphetamine resistant hypersonmia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.

Abstract: The present invention provides double-stranded RNA (dsRNA) compounds comprising a sense and antisense strand, wherein at least one strand is conjugated to a moiety comprising a phenyl hydrocarbyl group, pharmaceutical compositions comprising same and uses thereof.

Abstract: The invention relates to preparations comprising vitamin B12 and a butanol, and to the use of butanol for stabilizing vitamins.

Abstract: The invention relates to topical pharmaceutical compositions and methods related to Borrelia burgdorferi toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by Borrelia burgdorferi and in particular for the prevention of Lyme disease.

Abstract: Disclosed is a process for the preparation of partricin alkyl esters which involves reacting partricin in a solvent with primary alkyl alcohols in the quantity of 5 to 1000 moles per mole of partricin in the presence of carbodiimides, and optionally in the presence of acylation catalysts and/or nitrogen bases or anhydrous acids.